Blood markers may flag lung transplant danger — study investigates

NCT ID NCT00552357

Recruiting now Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

Primary graft dysfunction (PGD) is a serious lung complication that can develop shortly after a lung transplant. This study looks at blood samples from people receiving a lung or combined heart-lung transplant to see whether high levels of certain chemicals are linked to a higher risk of PGD. The goal is to better understand who is most at risk and why.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If certain chemicals are linked to PGD risk, it could help doctors identify high-risk patients earlier and tailor post-transplant care.
What could go wrong: This is an observational study, not a treatment trial. It may find no clear link, or the chemicals identified may not be useful for predicting PGD in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Primary Graft Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TRANSPLANTATION PRIMARY GRAFT DYSFUNCTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.